Document:

<PAGE>

                                                                    EXHIBIT 10.8

                             MEDIQUIK SERVICES INC.
                            PLACEMENT AGENT AGREEMENT

                                                        Dated as of: May 2, 2002

Westrock Advisors, Inc.
230 Park Avenue, Floor 9
New York, New York 10169

Ladies and Gentlemen:

         The undersigned, MediQuik Services Inc., a Delaware corporation (the
"Company"), hereby agrees with Westrock Advisors, a New York Corporation (the
"Placement Agent") and Cornell Capital Partners, LP, A Delaware Limited
Partnership (the "Investor") as follows:

         1.       Offering. The Company hereby engages the Placement Agent to
act as its exclusive placement agent in connection with the Equity Line of
Credit Agreement dated the date hereof, (the "Equity Line of Credit Agreement")
pursuant to which the Company shall issue and sell to the Investor, from time to
time, and the Investor shall purchase from the Company (the "Offering") up to
Five Million Dollars ($5,000,000) of the Company's common stock (the "Commitment
Amount"), par value $.001 per share (the "Common Stock"), at price per share
equal to the Purchase Price, as that term is defined in the Equity Line of
Credit Agreement. Pursuant to the terms hereof, the Placement Agent shall render
consulting services to the Company with respect to the Equity Line of Credit
Agreement and shall be available for consultation in connection with the
advances to be requested by the Company pursuant to the Equity Line of Credit
Agreement.

         2.       All capitalized terms used herein and not otherwise defined
herein shall have the same meaning ascribed to them as in the Equity Line of
Credit Agreement. The Investor will be granted certain registration rights with
respect to the Common Stock as more fully set forth in the Registration Rights
Agreement between the Company and the Investor dated the date hereof (the
"Registration Rights Agreement"). The documents to be executed and delivered in
connection with the Offering, including, but not limited, to this Agreement, the
Equity Line of Credit Agreement, the Registration Rights Agreement, and the
Escrow Agreement with First Union National Bank (the "Escrow Agreement"), are
referred to sometimes hereinafter collectively as the "Offering Materials." The
Company's Common Stock is sometimes referred to hereinafter

<PAGE>

as the "Securities." The Placement Agent shall not be obligated to sell any
Securities and this Offering by the Placement Agent shall be solely on a "best
efforts basis."

         2.       Compensation.

                  Upon the execution of this Agreement the Company shall issue
to the Placement Agent or its designee an amount equal to thirty five thousand
seven hundred fourteen (35,714) shares of the Company's Common Stock
(collectively, the "Placement Agent's Shares "). The Placement Agent shall be
entitled to "piggy-back" registration rights triggered upon registration of any
shares of Common Stock by the Investor with respect to the Placement Agent's
Shares pursuant to the Registration Rights Agreement dated the date hereof.

         3.       Representations, Warranties and Covenants of the Placement
                  Agent.

                  The Placement Agent represents, warrants and covenants as
follows:

                  (i) The Placement Agent has the necessary power to enter into
this Agreement and to consummate the transactions contemplated hereby.

                  (ii) The execution and delivery by the Placement Agent of this
Agreement and the consummation of the transactions contemplated herein will not
result in any violation of, or be in conflict with, or constitute a default
under, any agreement or instrument to which the Placement Agent is a party or by
which the Placement Agent or its properties are bound, or any judgment, decree,
order or, to the Placement Agent's knowledge, any statute, rule or regulation
applicable to the Placement Agent. This Agreement when executed and delivered by
the Placement Agent, will constitute the legal, valid and binding obligations of
the Placement Agent, enforceable in accordance with their respective terms,
except to the extent that (a) the enforceability hereof or thereof may be
limited by bankruptcy, insolvency, reorganization, moratorium or similar laws
from time to time in effect and affecting the rights of creditors generally, (b)
the enforceability hereof or thereof is subject to general principles of equity,
or (c) the indemnification provisions hereof or thereof may be held to be in
violation of public policy.

                  (iii) Upon receipt and execution of this Agreement the
Placement Agent will promptly forward copies of this Agreement to the Company or
its counsel and the Investor or its counsel.

                  (iv) The Placement Agent will not intentionally take any
action that it reasonably believes would cause the Offering to violate the
provisions of the Securities Act of 1933, as amended (the "1933 Act"), the
Securities Exchange Act of 1934 (the "1934 Act"), the respective rules and
regulations promulgated there under (the "Rules and Regulations") or applicable
"Blue Sky" laws of any state or jurisdiction.

                  (v) The Placement Agent will use all reasonable efforts to
determine (a) whether the Investor is an Accredited Investor and (b) that any
information furnished by the Investor is true and accurate. The Placement Agent
shall have no obligation to insure that (x) any check, note, draft or other
means of payment for the Common Stock will be honored, paid or enforceable
against the Investor in accordance with its terms, or (y) subject to the
performance of the Placement Agent's obligations and the accuracy of the
Placement Agent's representations and warranties hereunder, (1) the Offering is
exempt from the registration requirements of the 1933 Act or any applicable
state "Blue Sky" law or (2) the Investor is an Accredited Investor.

                  (vi) The Placement Agent is a member of the National
Association of Securities Dealers, Inc., and is a broker-dealer registered as
such under the 1934 Act and under

                                        2

<PAGE>

the securities laws of the states in which the Securities will be offered or
sold by the Placement Agent unless an exemption for such state registration is
available to the Placement Agent. The Placement Agent is in compliance with all
material rules and regulations applicable to the Placement Agent generally and
applicable to the Placement Agent's participation in the Offering.

                  (vii) The Placement Agent has such knowledge and experience in
financial, tax and business matters as to be capable of evaluating the merits
and risks of, bearing the economic risks entailed by an investment in the
Company and protecting its interests in connection with this transaction. It
recognizes that its investment in the Company involves a high degree of risk.

                  (viii) The Placement Agent acknowledges that it had the
opportunity to review this Agreement and the transactions contemplated by this
Agreement with his or its own counsel and investment and tax advisors. The
Placement Agent is relying solely on such counsel and advisors and not on any
statements or representations of the Company or any of its representatives or
agents for legal, tax or investment advice with respect to this investment, the
transactions contemplated by this Agreement and the securities laws of any
jurisdictions

                  (ix) The securities are being acquired by the Placement Agent
for its account, for investment and without any view to the distribution,
assignment or resale to others or fractionalization in whole in part. The
Placement agrees not to assign or in any way transfer the Placement Agent's
rights to the securities or any interest therein and acknowledges that the
Company will not recognize assignment or transfer except in accordance with
applicable Federal and state securities laws. No other person has or will have a
direct or indirect beneficial interest in the securities. The Placement Agent
agrees not to sell, hypothecate or otherwise transfer the Placement Agent's
securities unless the securities are registered under Federal and applicable
state securities laws or unless, an exemption from such laws are available.

                  (x) The Placement Agent is an "Accredited Investor" as that
term is defined in Rule 501(a)(3) of Regulation D of the Securities Act.

                  (xi) The Placement Agent and its advisors (and its counsel),
if any, have been furnished with all materials relating to the business,
finances and operations of the Company and information it deemed material to
making an informed investment decision. The Placement Agent and its advisors, if
any, have been afforded the opportunity to ask questions of the Company and its
management. Neither such inquiries nor any other due diligence investigations
conducted by such Placement Agent or its advisors, if any, or its
representatives shall modify, amend or affect the Placement Agent's right to
rely on the Company's representations and warranties contained in this
Agreement. The Placement Agent understands that its investment involves a high
degree of risk. The Placement Agent is in a position regarding the Company,
which, based upon employment, family relationship or economic bargaining power,
enabled and enables such Placement Agent to obtain information from the Company
in order to evaluate the merits and risks of this investment. The Placement
Agent has sought such accounting, legal and tax advice, as it has considered
necessary to make an informed investment decision with respect to this
transaction.

                                        3

<PAGE>

                  (xii) The Placement Agent and its counsel has received and
read in their entirety: (i) this Agreement and the Exhibits annexed hereto; (ii)
all due diligence and other information necessary to verify the accuracy and
completeness of such representations, warranties and covenants; (iii) the
Company's Form 10-KSB for the year ended year ended December 31, 2001 and Form
lO-QSB for the periods ended June 30, 2001 and September 30, 2001; and (iv)
answers to all questions the Placement Agent submitted to the Company regarding
an investment in the Company; and the Placement Agent acknowledges it has relied
on the information contained therein and has not been furnished any other
documents, literature, memorandum or prospectus.

                  (xiii) The Placement Agent is not an officer, director or a
person that directly, or indirectly through one or more intermediaries, controls
or is controlled by, or is under common control with the Company or any
"Affiliate" of the Company (as that term is defined in Rule 405 of the
Securities Act). Neither the Placement Agent nor its Affiliates has an open
short position in the Common Stock of the Company, and the Placement Agent
agrees that it will not and that it will cause its Affiliates not to, engage in
any short sales of or hedging transactions with respect to the Common Stock.

         4.       Representations and Warranties of the Company.

                  The Company represents and warrants as follows:

                  (i) The execution, delivery and performance of this Agreement,
has been or will be duly and validly authorized by the Company and this
Agreement is, a valid and binding agreement of the Company, enforceable in
accordance with its respective terms, except to the extent that (a) the
enforceability hereof may be limited by bankruptcy, insolvency, reorganization,
moratorium or similar laws from time to time in effect and affecting the rights
of creditors generally, (b) the enforceability hereof is subject to general
principles of equity or (c) the indemnification provisions hereof may be held to
be in violation of public policy. The Securities to be issued pursuant to the
transactions contemplated by this Agreement have been duly authorized and, when
issued and paid for in accordance with this Agreement, and the
certificates/instruments representing such Securities, will be valid and binding
obligations of the Company, enforceable in accordance with their respective
terms, except to the extent that (1) the enforceability thereof may be limited
by bankruptcy, insolvency, reorganization, moratorium or similar laws from time
to time in effect and affecting the rights of creditors generally, and (2) the
enforceability thereof is subject to general principles of equity. All corporate
action required to be taken for the authorization, issuance and sale of the
Securities has been duly and validly taken by the Company.

                  (ii) The Company has a duly authorized, issued and outstanding
capitalization as set forth herein. The Company is not a party to or bound by
any instrument, agreement or other arrangement providing for it to issue any
capital stock, rights, warrants, options or other securities, except for this
Agreement, the agreements described herein and as described in the Equity Line
of Credit Agreement, dated the date hereof and the agreements described therein.
All issued and outstanding securities of the Company, have been duly authorized
and validly issued and are fully paid and non-assessable; the holders thereof
have no rights of rescission or preemptive rights with respect thereto and are
not subject to personal liability solely by reason of

                                        4

<PAGE>

being security holders; and none of such securities were issued in violation of
the preemptive rights of any holders of any security of the Company. As of the
date hereof, the authorized capital stock of the Company consists of 50,000,000
shares of Common Stock, par value $.00l per share of which 11,085,528 shares of
Common Stock are issued and outstanding and 1,000,000 shares of Preferred Stock,
4,500 of which are outstanding.

                  (iii) The Common Stock to be issued in accordance with this
Agreement and the Equity Line of Credit Agreement has been duly authorized and
when issued and paid for in accordance with this Agreement the Equity Line of
Credit Agreement and the certificates/instruments representing such Common
Stock, will be validly issued, fully-paid and non-assessable; the holders
thereof will not be subject to personal liability solely by reason of being such
holders; such Securities are not and will not be subject to the preemptive
rights of any holder of any security of the Company.

                  (iv) The Company has good and marketable title to, or valid
and enforceable leasehold estates in, all items of real and personal property
necessary to conduct its business (including, without limitation, any real or
personal property stated in the Offering Materials to be owned or leased by the
Company), free and clear of all liens, encumbrances, claims, security interests
and defects of any material nature whatsoever, other than those set forth in the
Offering Materials and liens for taxes not yet due and payable.

                  (v) There is no litigation or governmental proceeding pending
or, to the best of the Company's knowledge, threatened against, or involving the
properties or business of the Company, except as set forth in the Offering
Materials.

                  (vi) The Company has been duly organized and is validly
existing as a corporation in good standing under the laws of the State of
Delaware. Except as set forth in the Offering Materials, the Company does not
own or control, directly or indirectly, an interest in any other corporation,
partnership, trust, joint venture or other business entity. The Company is duly
qualified or licensed and in good standing as a foreign corporation in each
jurisdiction in which the character of its operations requires such
qualification or licensing and where failure to so qualify would have a material
adverse effect on the Company. The Company has all requisite corporate power and
authority, and all material and necessary authorizations, approvals, orders,
licenses, certificates and permits of and from all governmental regulatory
officials and bodies (domestic and foreign) to conduct its businesses (and
proposed business) as described in the Offering Materials. Any disclosures in
the Offering Materials concerning the effects of foreign, federal, state and
local regulation on the Company's businesses as currently conducted and as
contemplated are correct in all material respects and do not omit to state a
material fact. The Company has all corporate power and authority to enter into
this Agreement and to carry out the provisions and conditions hereof and all
consents, authorizations, approvals and orders required in connection herewith
have been obtained. No consent, authorization or order of, and no filing with,
any court, government agency or other body is required by the Company for the
issuance of the Securities or execution and delivery of the Offering Materials
except for applicable federal and state securities laws. The Company, since its
inception, has not incurred any liability arising under or as a result of the
application of any of the provisions of the 1933 Act, the 1934 Act or the Rules
and Regulations.

                  (vii) There has been no material adverse change in the
condition or prospects of the Company, financial or otherwise, from the latest
dates as of which such condition or prospects, respectively, are set forth in
the Offering Materials, and the outstanding debt, the

                                        5

<PAGE>

property and the business of the Company conform in all material respects to the
descriptions thereof contained in the Offering Materials.

                  (viii) Except as set forth in the Offering Materials, the
Company is not in breach of, or in default under, any term or provision of any
material indenture, mortgage, deed of trust, lease, note, loan or Equity Line of
Credit Agreement or any other material agreement or instrument evidencing an
obligation for borrowed money, or any other material agreement or instrument to
which it is a party or by which it or any of its properties may be bound or
affected. The Company is not in violation of any provision of its charter or
by-laws or in violation of any franchise, license, permit, judgment, decree or
order, or in violation of any material statute, rule or regulation. Neither the
execution and delivery of the Offering Materials nor the issuance and sale or
delivery of the Securities, nor the consummation of any of the transactions
contemplated in the Offering Materials nor the compliance by the Company with
the terms and provisions hereof or thereof, has conflicted with or will conflict
with, or has resulted in or will result in a breach of, any of the terms and
provisions of, or has constituted or will constitute a default under, or has
resulted in or will result in the creation or imposition of any lien, charge or
encumbrance upon any property or assets of the Company or pursuant to the terms
of any indenture, mortgage, deed of trust, note, loan or any other agreement or
instrument evidencing an obligation for borrowed money, or any other agreement
or instrument to which the Company may be bound or to which any of the property
or assets of the Company is subject except (a) where such default, lien, charge
or encumbrance would not have a material adverse effect on the Company and (b)
as described in the Offering Materials; nor will such action result in any
violation of the provisions of the charter or the by-laws of the Company or,
assuming the due performance by the Placement Agent of its obligations
hereunder, any material statute or any material order, rule or regulation
applicable to the Company of any court or of any foreign, federal, state or
other regulatory authority or other government body having jurisdiction over the
Company.

                  (ix) Subsequent to the dates as of which information is given
in the Offering Materials, and except as may otherwise be indicated or
contemplated herein, the Company has not (a) issued any securities or incurred
any liability or obligation, direct or contingent for borrowed money, or (b)
entered into any transaction other than in the ordinary course of business, or
(c) declared or paid any dividend or made any other distribution on or in
respect of its capital stock. Except as described in the Offering Materials, the
Company has no outstanding obligations to any officer or director of the
Company.

                  (x) There are no claims for services in the nature of a
finder's or origination fee with respect to the sale of the Common Stock or any
other arrangements, agreements or understandings that may affect the Placement
Agent's compensation, as determined by the National Association of Securities
Dealers, Inc.

                  (xi) The Company owns or possesses, free and clear of all
liens or encumbrances and rights thereto or therein by third parties, the
requisite licenses or other rights to use all trademarks, service marks,
copyrights, service names, trade names, patents, patent applications and
licenses necessary to conduct its business (including, without limitation, any
such licenses or rights described in the Offering Materials as being owned or
possessed by the Company) and, except as set forth in the Offering Materials,
there is no claim or action by any person pertaining to, or proceeding, pending
or threatened, which challenges the exclusive rights of the Company with respect
to any trademarks, service marks, copyrights, service names, trade names,
patents, patent applications and licenses used in the conduct of the Company's
businesses

                                        6

<PAGE>

(including, without limitation, any such licenses or rights described in the
Offering Materials as being owned or possessed by the Company) except any claim
or action that would not have a material adverse effect on the Company; the
Company's current products, services or processes do not infringe or will not
infringe on the patents currently held by any third party.

                  (xii) Except as described in the Offering Materials, the
Company is not under any obligation to pay royalties or fees of any kind
whatsoever to any third party with respect to any trademarks, service marks,
copyrights, service names, trade names, patents, patent applications, licenses
or technology it has developed, uses, employs or intends to use or employ, other
than to their respective licensors.

                  (xiii) Subject to the performance by the Placement Agent of
its obligations hereunder and the offer and sale of the Securities comply, and
will continue to comply in all material respects with the requirements of Rule
506 of Regulation D promulgated by the SEC pursuant to the 1933 Act and any
other applicable federal and state laws, rules, regulations and executive
orders. Neither the Offering Materials nor any amendment or supplement thereto
nor any documents prepared by the Company in connection with the Offering will
contain any untrue statement of a material fact or omit to state any material
fact required to be stated therein or necessary to make the statements therein,
in light of the circumstances under which they were made, not misleading. All
statements of material facts in the Offering Materials are true and correct as
of the date of the Offering Materials.

                  (xiv) All material taxes which are due and payable from the
Company have been paid in full or adequate provision has been made for such
taxes on the books of the Company except for those taxes disputed in good faith
the Company does not have any tax deficiency or claim outstanding assessed or
proposed against it.

                  (xv) Neither of the Company nor any of its officers,
directors, employees or agents, nor any other person acting on behalf of the
Company, has, directly or indirectly, given or agreed to give any money, gift or
similar benefit (other than legal price concessions to customers in the ordinary
course of business) to any customer, supplier, employee or agent of a customer
or supplier, or official or employee of any governmental agency or
instrumentality of any government (domestic or foreign) or any political party
or candidate for office (domestic or foreign) or other person who is or may be
in a position to help or hinder the business of the Company (or assist it in
connection with any actual or proposed transaction) which (A) might subject the
Company to any damage or penalty in any civil, criminal or governmental
litigation or proceeding, or (B) if not given in the past, might have had a
materially adverse effect on the assets, business or operations of the Company
as reflected in any of the financial statements contained in the Offering
Materials, or (C) if not continued in the future, might adversely affect the
assets, business, operations or prospects of the Company in the future.

         5.       Representations, Warranties and Covenants of the Investor.

         A.       The Investor represents, warrants and covenants as follows:

                  (i) The Investor has the necessary power to enter into this
Agreement and to consummate the transactions contemplated hereby.

                  (ii) The execution and delivery by the Investor of this
Agreement and the consummation of the transactions contemplated herein will not
result in any violation of, or be in conflict with, or constitute a default
under, any agreement or instrument to which the Investor is a party or by which
the Investor or its properties are bound, or any judgment, decree, order or, to

                                        7

<PAGE>

the Investor's knowledge, any statute, rule or regulation applicable to the
Investor. This Agreement when executed and delivered by the Investor, will
constitute the legal, valid and binding obligations of the Investor, enforceable
in accordance with their respective terms, except to the extent that (a) the
enforceability hereof or thereof may be limited by bankruptcy, insolvency,
reorganization, moratorium or similar laws from time to time in effect and
affecting the rights of creditors generally, (b) the enforceability hereof or
thereof is subject to general principles of equity, or (c) the indemnification
provisions hereof or thereof may be held to be in violation of public policy.

                  (iii) The Investor will promptly forward copies of any and all
due diligence questionnaires compiled by the Investor to the Placement Agent.

         6. Certain Covenants and Agreements of the Company.

         The Company covenants and agrees at its expense and without any expense
to the Placement Agent as follows:

         A. To advise the Placement Agent of any material adverse change in the
Company's financial condition, prospects or business or of any development
materially affecting the Company or rendering untrue or misleading any material
statement in the Offering Materials occurring at any time as soon as the Company
is either informed or becomes aware thereof

         B. To use its commercially reasonable efforts to cause the Common Stock
issuable in connection with the Equity Line of Credit to be qualified or
registered for sale on terms consistent with those stated in the Registration
Rights Agreement and under the securities laws of such jurisdictions as the
Placement Agent and the Investor shall reasonably request. Qualification,
registration and exemption charges and fees shall be at the sole cost and
expense of the Company.

         C. Upon written request, to provide and continue to provide the
Placement Agent and the Investor copies of all quarterly financial statements
and audited annual financial statements prepared by or on behalf of the Company,
other reports prepared by or on behalf of the Company for public disclosure and
all documents delivered to the Company's stockholders.

         D. To deliver, during the registration period of the Equity Line Credit
Agreement, to the Placement Agent upon the Placement Agent's request, within
forty five (45) days, a statement of its income for each such quarterly period,
and its balance sheet and a statement of changes in stockholders' equity as of
the end of such quarterly period, all in reasonable detail, certified by its
principal financial or accounting officer; (ii) within ninety (90) days after
the close of each fiscal year, its balance sheet as of the close of such fiscal
year, together with a statement of income, a statement of changes in
stockholders' equity and a statement of cash flow for such fiscal year, such
balance sheet, statement of income, statement of changes in stockholders' equity
and statement of cash flow to be in reasonable detail and accompanied by a copy
of the certificate or report thereon of independent auditors if audited
financial statements are prepared; and (iii) a copy of all documents, reports
and information furnished to its stockholders at the time that such documents,
reports and information are furnished to its stockholders.

         E. To comply with the terms of the Offering Materials.

         F. To ensure that any transactions between or among the Company, or any
of its officers, directors and affiliates be on terms and conditions that are no
less favorable to the

                                        8

<PAGE>

Company, than the terms and conditions that would be available in an "arm's
length" transaction with an independent third party.

         7.       Indemnification.

                  A. The Company hereby agrees that it will indemnify and hold
the Placement Agent and each officer, director, shareholder, employee or
representative of the Placement Agent and each person controlling, controlled by
or under common control with the Placement Agent within the meaning of Section
15 of the 1933 Act or Section 20 of the 1934 Act or the SEC's Rules and
Regulations promulgated there under (the "Rules and Regulations"), harmless from
and against any and all loss, claim, damage, liability, cost or expense
whatsoever (including, but not limited to, any and all reasonable legal fees and
other expenses and disbursements incurred in connection with investigating,
preparing to defend or defending any action, suit or proceeding, including any
inquiry or investigation, commenced or threatened, or any claim whatsoever or in
appearing or preparing for appearance as a witness in any action, suit or
proceeding, including any inquiry, investigation or pretrial proceeding such as
a deposition) to which the Placement Agent or such indemnified person of the
Placement Agent may become subject under the 1933 Act, the 1934 Act, the Rules
and Regulations, or any other federal or state law or regulation, common law or
otherwise, arising out of or based upon (i) any untrue statement or alleged
untrue statement of a material fact contained in (a) Section 4 of this
Agreement, (b) the Offering Materials (except those written statements relating
to the Placement Agent given by an indemnified person for inclusion therein),
(c) any application or other document or written communication executed by the
Company or based upon written information furnished by the Company filed in any
jurisdiction in order to qualify the Common Stock under the securities laws
thereof, or any state securities commission or agency; (ii) the omission or
alleged omission from documents described in clauses (a), (b) or (c) above of a
material fact required to be stated therein or necessary to make the statements
therein not misleading; or (iii) the breach of any representation, warranty,
covenant or agreement made by the Company in this Agreement. The Company further
agrees that upon demand by an indemnified person, at any time or from time to
time, it will promptly reimburse such indemnified person for any loss, claim,
damage, liability, cost or expense actually and reasonably paid by the
indemnified person as to which the Company has indemnified such person pursuant
hereto. Notwithstanding the foregoing provisions of this Paragraph 7(A), any
such payment or reimbursement by the Company of fees, expenses or disbursements
incurred by an indemnified person in any proceeding in which a final judgment by
a court of competent jurisdiction (after all appeals or the expiration of time
to appeal) is entered against the Placement Agent or such indemnified person
based upon specific finding of fact that the Placement Agent or such indemnified
person's gross negligence or willful misfeasance will be promptly repaid to the
Company.

                  B. The Placement Agent hereby agrees that it will indemnify
and hold the Company and each officer, director, shareholder, employee or
representative of the Company, and each person controlling, controlled by or
under common control with the Company within the meaning of Section 15 of the
1933 Act or Section 20 of the 1934 Act or the Rules and Regulations, harmless
from and against any and all loss, claim, damage, liability, cost or expense
whatsoever (including, but not limited to, any and all reasonable legal fees and
other expenses and disbursements incurred in connection with investigating,
preparing to defend or defending any action, suit or proceeding, including any
inquiry or investigation, commenced or threatened,

                                        9

<PAGE>

or any claim whatsoever or in appearing or preparing for appearance as a witness
in any action, suit or proceeding, including any inquiry, investigation or
pretrial proceeding such as a deposition) to which the Company or such
indemnified person of the Company may become subject under the 1933 Act, the
1934 Act, the Rules and Regulations, or any other federal or state law or
regulation, common law or otherwise, arising out of or based upon (i) the
conduct of the Placement Agent or its officers, employees or representatives in
its acting as Placement Agent for the Offering or (ii) the material breach of
any representation, warranty, covenant or agreement made by the Placement Agent
in this Agreement (iii) any false or misleading information provided to the
Company by one of the Placement Agent's indemnified persons.

         C. The Investor hereby agrees that it will indemnify and hold the
Placement Agent and each officer, director, shareholder, employee or
representative of the Placement Agent, and each person controlling, controlled
by or under common control with the Placement Agent within the meaning of
Section 15 of the 1933 Act or Section 20 of the 1934 Act or the Rules and
Regulations, harmless from and against any and all loss, claim, damage,
liability, cost or expense whatsoever (including, but not limited to, any and
all reasonable legal fees and other expenses and disbursements incurred in
connection with investigating, preparing to defend or defending any action, suit
or proceeding, including any inquiry or investigation, commenced or threatened,
or any claim whatsoever or in appearing or preparing for appearance as a witness
in any action, suit or proceeding, including any inquiry, investigation or
pretrial proceeding such as a deposition) to which the Placement Agent or such
indemnified person of the Placement Agent may become subject under the 1933 Act
the 1934 Act, the Rules and Regulations, or any other federal or state law or
regulation, common law or otherwise, arising out of or based upon (i) the
conduct of the Investor or its officers, employees or representatives in its
acting as the Investor for the Offering or (ii) the material breach of any
representation, warranty, covenant or agreement made by the Investor in the
Offering Materials (iii) any false or misleading information provided to the
Placement Agent by one of the Investor's indemnified persons.

         D. The Placement Agent hereby agrees that it will indemnify and hold
the Investor and each officer, director, shareholder, employee or representative
of the Investor, and each person controlling, controlled by or under common
control with the Investor within the meaning of Section 15 of the 1933 Act or
Section 20 of the 1934 Act or the Rules and Regulations, harmless from and
against any and all loss, claim, damage, liability, cost or expense whatsoever
(including, but not limited to, any and all reasonable legal fees and other
expenses and disbursements incurred in connection with investigating, preparing
to defend or defending any action, suit or proceeding, including any inquiry or
investigation, commenced or threatened, or any claim whatsoever or in appearing
or preparing for appearance as a witness in any action, suit or proceeding,
including any inquiry, investigation or pretrial proceeding such as a
deposition) to which the Investor or such indemnified person of the Investor may
become subject under the 1933 Act, the 1934 Act, the Rules and Regulations, or
any other federal or state law or regulation, common law or otherwise, arising
out of or based upon (i) the conduct of the Placement Agent or its officers,
employees or representatives in its acting as the Placement Agent for the
Offering or (ii) the material breach of any representation, warranty, covenant
or agreement made by the Placement Agent in this Agreement (iii) any false or
misleading information provided to the Investor by one of the Placement Agent's
indemnified persons.

                                       10

<PAGE>

         E. Promptly after receipt by an indemnified party of notice of
commencement of any action covered by Section 7(A), (B), (C) or (D), the party
to be indemnified shall, within five (5) business days, notify the indemnifying
party of the commencement thereof; the omission by one (1) indemnified party to
so notify the indemnifying party shall not relieve the indemnifying party of its
obligation to indemnify any other indemnified party that has given such notice
and shall not relieve the indemnifying party of any liability outside of this
indemnification if not materially prejudiced thereby. In the event that any
action is brought against the indemnified party, the indemnifying party will be
entitled to participate therein and, to the extent it may desire, to assume and
control the defense thereof with counsel chosen by it which is reasonably
acceptable to the indemnified party. After notice from the indemnifying party to
such indemnified party of its election to so assume the defense thereof, the
indemnifying party will not be liable to such indemnified party under such
Section 7(A), (B), (C), or (D) for any legal or other expenses subsequently
incurred by such indemnified party in connection with the defense thereof, but
the indemnified party may, at its own expense, participate in such defense by
counsel chosen by it, without, however, impairing the indemnifying party's
control of the defense. Subject to the proviso of this sentence and
notwithstanding any other statement to the contrary contained herein, the
indemnified party or parties shall have the right to choose its or their own
counsel and control the defense of any action, all at the expense of the
indemnifying party if, (i) the employment of such counsel shall have been
authorized in writing by the indemnifying party in connection with the defense
of such action at the expense of the indemnifying party, or (ii) the
indemnifying party shall not have employed counsel reasonably satisfactory to
such indemnified party to have charge of the defense of such action within a
reasonable time after notice of commencement of the action, or (iii) such
indemnified party or parties shall have reasonably concluded that there may be
defenses available to it or them which are different from or additional to those
available to one or all of the indemnifying parties (in which case the
indemnifying parties shall not have the right to direct the defense of such
action on behalf of the indemnified party or parties), in any of which events
such fees and expenses of one additional counsel shall be borne by the
indemnifying party; provided, however, that the indemnifying party shall not, in
connection with any one action or separate but substantially similar or related
actions in the same jurisdiction arising out of the same general allegations or
circumstance, be liable for the reasonable fees and expenses of more than one
separate firm of attorneys at any time for all such indemnified parties. No
settlement of any action or proceeding against an indemnified party shall be
made without the consent of the indemnifying party.

         F. In order to provide for just and equitable contribution in
circumstances in which the indemnification provided for in Section 7(A) or 7(B)
is due in accordance with its terms but is for any reason held by a court to be
unavailable on grounds of policy or otherwise, the Company and the Placement
Agent shall contribute to the aggregate losses, claims, damages and liabilities
(including legal or other expenses reasonably incurred in connection with the
investigation or defense of same) which the other may incur in such proportion
so that the Placement Agent shall be responsible for such percent of the
aggregate of such losses, claims, damages and liabilities as shall equal the
percentage of the gross proceeds paid to the Placement Agent and the Company
shall be responsible for the balance; provided, however, that no person guilty
of fraudulent misrepresentation within the meaning of Section 11(f) of the 1933
Act shall be entitled to contribution from any person who was not guilty of such
fraudulent

                                       11

<PAGE>

misrepresentation. For purposes of this Section 7(F), any person controlling,
controlled by or under common control with the Placement Agent, or any partner,
director, officer, employee, representative or any agent of any thereof, shall
have the same rights to contribution as the Placement Agent and each person
controlling, controlled by or under common control with the Company within the
meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act and each
officer of the Company and each director of the Company shall have the same
rights to contribution as the Company. Any party entitled to contribution will,
promptly after receipt of notice of commencement of any action, suit or
proceeding against such party in respect of which a claim for contribution may
be made against the other party under this paragraph 7(F), notify such party
from whom contribution may be sought, but the omission to so notify such party
shall not relieve the party from whom contribution may be sought from any
obligation they may have hereunder or otherwise if the party from whom
contribution may be sought is not materially prejudiced thereby. The indemnity
and contribution agreements contained in this Section 6 shall remain operative
and in full force and effect regardless of any investigation made by or on
behalf of any indemnified person or any termination of this Agreement.

         8.       Payment of Expenses.

         The Company hereby agrees to bear all of the expenses in connection
with the Offering, including, but not limited to the following: filing fees,
printing and duplicating costs, advertisements, postage and mailing expenses
with respect to the transmission of Offering Materials, registrar and transfer
agent fees, escrow agent fees and expenses, fees of the Company's counsel and
accountants, issue and transfer taxes, if any.

         9.       Conditions of Closing

         The Closing shall be held at the offices of the Investor or its
counsel. The obligations of the Placement Agent hereunder shall be subject to
the continuing accuracy of the representations and warranties of the Company
herein as of the date hereof and as of the Date of Closing (the "Closing Date")
with respect to the Company as if it had been made on and as of such Closing
Date; the accuracy on and as of the Closing Date of the statements of the
officers of the Company made pursuant to the provisions hereof; and the
performance by the Company on and as of the Closing Date of its covenants and
obligations hereunder and to the following further conditions:

         A. At or prior to the Closing, the Placement Agent shall have been
furnished such documents, certificates and opinions as it may reasonably require
for the purpose of enabling them to review or pass upon the matters referred to
in this Agreement and the Offering Materials, or in order to evidence the
accuracy, completeness or satisfaction of any of the representations, warranties
or conditions herein contained.

         B. At and prior to the Closing, (i) there shall have been no material
adverse change nor development involving a prospective change in the condition
or prospects or the business activities, financial or otherwise, of the Company
from the latest dates as of which such condition is set forth in the Offering
Materials; (ii) there shall have been no transaction, not in the ordinary course
of business except the transactions pursuant to the Securities Purchase
Agreement entered into by the Company which has not been disclosed in the
Offering Materials or to the Placement Agent in writing; (iii) except as set
forth in the Offering Materials, the

                                       12

<PAGE>

Company shall not be in default under any provision of any instrument relating
to any outstanding indebtedness for which a waiver or extension has not been
otherwise received; (iv) except as set forth in the Offering Materials, the
Company shall not have issued any securities (other than those to be issued as
provided in the Offering Materials) or declared or paid any dividend or made any
distribution of its capital stock of any class and there shall not have been any
change in the indebtedness (long or short term) or liabilities or obligations of
the Company (contingent or otherwise) and trade payable debt; (v) no material
amount of the assets of the Company shall have been pledged or mortgaged, except
as indicated in the Offering Materials; and (v) no action, suit or proceeding,
at law or in equity, against the Company or affecting any of its properties or
businesses shall be pending or threatened before or by any court or federal or
state commission, board or other administrative agency, domestic or foreign,
wherein an unfavorable decision, ruling or finding could materially adversely
affect the businesses, prospects or financial condition or income of the
Company, except as set forth in the Offering Materials.

                  C. At Closing, the Placement Agent shall receive a certificate
of the Company signed by an executive officer and chief financial officer, dated
as of the applicable Closing, to the effect that the conditions set forth in
subparagraph (B) above have been satisfied and that, as of the applicable
closing, the representations and warranties of the Company set forth herein are
true and correct.

         10.      Termination.

                  This Agreement shall be co-terminus with, and terminate upon
the same terms and conditions as those set forth in, the Equity Line of Credit
Agreement. The rights of the Investor and the obligations of the Company under
the Registration Rights Agreement, and the rights and obligations of the
Placement Agent and the Company shall survive the termination of this Agreement
unabridged.

         11.      Miscellaneous.

                  A. This Agreement may be executed in any number of
counterparts, each of which shall be deemed to be an original, but all which
shall be deemed to be one and the same instrument.

                  B. Any notice required or permitted to be given hereunder
shall be given in writing and shall be deemed effective when deposited in the
United States mail, postage prepaid, or when received if personally delivered or
faxed (upon confirmation of receipt received by the sending party), addressed as
follows:

                                       13
<PAGE>

If to Placement Agent, to:       Westrock Advisors, Inc.
                                 230 Park Avenue, Floor 9
                                 New York, New York 10169

If to the Company, to:           MediQuik Services Inc.
                                 4299 San Felipe -- Suite 300
                                 Houston, TX 77027
                                 Attention: Robert Teague
                                 Telephone: (832) 200-7000
                                 Facsimile: (832) 888-1985

With a copy to:                  Franklin, Cardwell & Jones
                                 1001 McKinney -- l8th Floor
                                 Attention: Lawrence E. Wilson
                                 Telephone: (713) 222-6025
                                 Facsimile: (713) 222-0938

If to the Investor:              Cornell Capital Partners, LP
                                 101 Hudson Street -- Suite 3606
                                 Jersey City, NJ 07302
                                 Attention: Mark A. Angelo
                                            Portfolio Manager
                                 Telephone: (201) 985-8300
                                 Facsimile: (201) 985-8266

With Copies to:                  Butler Gonzalez LLP
                                 1000 Stuyvesant Avenue - Suite No.: 6
                                 Union, NJ 07083
                                 Attention: David Gonzalez, Esq.
                                 Telephone: (908) 810-8588
                                 Facsimile: (908) 810-0973

or to such other address of which written notice is given to the others.

         C. This Agreement shall be governed by and construed in all respects
under the laws of the State of New York, without reference to its conflict of
laws rules or principles. Any suit, action, proceeding or litigation arising out
of or relating to this Agreement shall be brought and prosecuted in such federal
or state court or courts located within the State of New York as provided by
law. The parties hereby irrevocably and unconditionally consent to the
jurisdiction of each such court or courts located within the State of New York
and to service of process by registered or certified mail, return receipt
requested, or by any other manner provided by applicable law, and hereby
irrevocably and unconditionally waive any right to claim that any suit, action,
proceeding or litigation so commenced has been commenced in an inconvenient
forum.

                                       14

<PAGE>

         D. This Agreement and the other agreements referenced herein contain
the entire understanding between the parties hereto and may not be modified or
amended except by a writing duly signed by the party against whom enforcement of
the modification or amendment is sought.

         E. If any provision of this Agreement shall be held to be invalid or
unenforceable, such invalidity or unenforceability shall not affect any other
provision of this Agreement.

                  [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

                                       15

<PAGE>

         IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the date first written above.

                                      COMPANY:
                                      MEDIQUIK SERVICES INC.

                                      By: /s/ ROBERT TEAGUE
                                         ----------------------------
                                      Name:  Robert Teague
                                      Title: Chief Executive Officer

                                      PLACEMENT AGENT:
                                      WESTROCK ADVISORS, INC.

                                      By: /s/ VICTOR T. SICURANZA
                                         ----------------------------
                                      Name:  Victor T. Sicuranza
                                      Title: Managing Director

                                      INVESTOR:
                                      CORNELL CAPITAL PARTNERS, LP

                                      By:  Yorkville Advisors, LLC
                                      Its: General Partner

                                      By: /s/ MARK A. ANGELO
                                         ----------------------------
                                      Name : Mark A. Angelo
                                      Title: Portfolio Manager

                                       16<PAGE>
                                                                    EXHIBIT 10.9

                                PAYMENT AGREEMENT

     This Payment Agreement ("this Agreement") is entered into as of April 30,
2002, between Bayer Corporation ("Bayer"), with offices at 511 Benedict Avenue,
Tarrytown, New York 10591-5097, and MediQuik Services, Inc. ("MediQuik"), with
offices at 4299 San Felipe, Suite 300, Houston, Texas 77027.

     WHEREAS, Bayer commenced a civil action (the "Action") against MediQuik in
the United States District Court for the Southern District of Texas, docketed at
No. H-00-4247, in which Action Bayer sought relief against MediQuik relating to
certain written agreements between Bayer and MediQuik; and

     WHEREAS, on December 21, 2001, the Court entered a judgment (the
"Judgment") in the Action for Bayer and against MediQuik, awarding compensatory
damages in the amount of $494,004.00 and prejudgment interest in the amount of
$125,790.46 to Bayer (such damages and prejudgment interest hereinafter are
referred to collectively as the "Judgment Amount"); and

     WHEREAS, on March 11, 2002, the Court entered an order in the Action
awarding attorneys' fees to Bayer in the amount of $118,829.65 (the "Fee
Amount"), and Bayer has filed a bill of costs in the Action, to which no
objection has been filed, for taxable costs in the amount of $11,939.83 (the
"Costs Amount"); and

     WHEREAS, MediQuik remains obligated to Bayer for unpaid invoices in the
total amount of $18,749.20 (the "Invoice Amount") for products sold and
delivered by Bayer to MediQuik; and

     WHEREAS, Bayer and MediQuik have agreed to a schedule for payment of
amounts owed by MediQuik to Bayer, including the Judgment Amount, the Fee
Amount, the Costs Amount and the Invoice Amount, which amounts (including
accrued interest), for purposes of

<PAGE>

this Agreement, Bayer and MediQuik have agreed totaled $770,000.00 (the
"MediQuik Obligation") as of January 1, 2002, with such payments (the
"Payments") to be made in accordance with and subject to the terms and
conditions set forth in this Agreement;

     NOW, THEREFORE, Bayer and MediQuik, intending to be legally bound hereby,
agree as follows:

     1. MediQuik shall pay to Bayer the total amount of the MediQuik Obligation,
along with additional interest to be calculated as provided in Paragraph 2 of
this Agreement, according to the following schedule of Payments:

        (a) MediQuik shall pay to Bayer 12 monthly Payments, each in the amount
of $7,500.00 per month, on or before the 15th day of each calendar month,
beginning on May 15, 2002, and continuing through April 15, 2003;

        (b) MediQuik shall pay to Bayer 12 monthly Payments, each in the amount
of $20,000.00 per month, on or before the 15th day of each calendar month,
beginning on May 15, 2003, and continuing through April 15, 2004; and

        (c) MediQuik shall pay to Bayer 15 monthly Payments, each in the amount
of $33,653.00 per month, on or before the 15th day of each calendar month,
beginning on May 15, 2004, and continuing though July 15, 2005.

        (d) Unless Bayer otherwise directs, all Payments to be made pursuant to
this Paragraph 1 shall be made by checks payable to Bayer Corporation, drawn on
accounts in which good and sufficient funds are deposited to ensure payment of
the checks by MediQuik's bank, and each such check shall be sent in such manner
that it is calculated to be received by Bayer at its offices in Tarrytown, New
York (Attention: Laura Mezey), on or before the date on which each such Payment
is due under the payment schedule in this Paragraph 1. All such Payments

                                       2
<PAGE>

shall be credited, as received by Bayer, toward the MediQuik Obligation. So long
as MediQuik makes timely Payments as provided in this Paragraph 1, Bayer shall
refrain from further efforts to enforce and/or collect the Judgment. In the
event that any such Payment is not received by Bayer on or before the due date
as provided in this Paragraph 1, Bayer may proceed immediately to take all
appropriate actions to enforce and/or collect the Judgment. For and in
consideration of Bayer's forebearance from enforcing the Judgment during
MediQuik's performance under this Agreement, MediQuik covenants and agrees that
MediQuik will not assert, and MediQuik hereby specifically waives, any and all
defenses to the execution and/or enforcement of the Judgment.

     2. The entire unpaid amount of the MediQuik Obligation shall bear interest,
at the rate of 3.5% per annum simple interest, until the MediQuik Obligation has
been paid in full. For purposes of calculating this interest obligation, Bayer
and MediQuik agree that the total amount of interest to accrue, assuming that
MediQuik makes all Payments in a timely manner as provided in Paragraph 1 of
this Agreement, shall total $64,810.00, which amount is included in the Payments
to be made as provided in subparagraph (c) of Paragraph 1 of this Agreement.
Additional interest, in the amount of 0.01% per diem, shall accrue, and shall be
paid to Bayer by MediQuik as it accrues, on any and all Payments that are not
paid when due as provided in Paragraph 1 of this Agreement.

     3. In the event that MediQuik has made Payments to Bayer in the total
amount of $500,000.00 after the date of this Agreement and on or before December
31, 2002, the entire MediQuik Obligation shall be deemed to have been paid in
full. In the event that MediQuik has made Payments to Bayer in the total amount
of $600,000.00 after the date of this Agreement and

                                       3
<PAGE>

on or before December 31, 2003, the entire MediQuik Obligation shall be deemed
to have been paid in full.

     4. In the event that, at any time after the date of this Agreement and
before the MediQuik Obligation has been paid in full, MediQuik obtains new
equity or debt financing ("Investment Funds"), as a result of which MediQuik
receives Investment Funds in the total amount of $100,000.00 or more, MediQuik
shall, immediately upon MediQuik's receipt of such funds, and unless and until
the MediQuik Obligation has been paid in full, pay to Bayer the following
amounts, calculated as a percentage of the total of such Investment Funds
received by MediQuik after the date of this Agreement:

        (a) 10% of all Investment Funds up to $250,000.00;

        (b) 12% of all Investment Funds in excess of $250,000.00 and up to
            $500,000.00; and

        (c) 15% of all Investment Funds in excess of $500,000.00.

All such Investment Funds paid by MediQuik to Bayer shall be credited against
MediQuik's then-existing Payment obligations pursuant to Paragraph 1 of this
Agreement, to the extent of the amount of such Investment Funds that are paid to
Bayer. To the extent that Bayer receives funds from First Bank & Trust, formerly
First Bank Texas, N.A. (the "Bank"), as garnishee in a writ of garnishment
served on the Bank in the Action, free and clear of any claims by any other
persons, firms or entities (including but not limited to the Bank, MediQuik
and/or their respective attorneys), such funds also will be credited against
MediQuik's then-existing Payment obligations pursuant to Paragraph 1 of this
Agreement, to the extent of the amount of such funds that are received by Bayer.

     5. In the event that MediQuik is or becomes the subject of a voluntary or
involuntary petition in bankruptcy (a "Petition"), pursuant to Title 11 of the
United States Code, filed within

                                       4
<PAGE>

105 calendar days after the date on which any Payment is made by MediQuik, Bayer
shall retain all of its rights to pursue any and all claims against MediQuik to
enforce and/or collect the Judgment and/or to collect the MediQuik Obligation,
except that Bayer shall be entitled to retain all Payments that have been
received by Bayer and Bayer's claims shall be reduced by the amount of such
Payments that have been received and that can be retained by Bayer,
notwithstanding the Petition. MediQuik and Bayer stipulate and agree that, in
entering into this Agreement, Bayer has agreed to forebear enforcement of the
Judgment in exchange for the timely receipt of Payments as set forth in this
Agreement. Bayer and MediQuik stipulate and agree that, in holding the Judgment,
on a month-to-month basis, Bayer is providing new value to MediQuik, as that
term is used in 11 U.S.C. Section 547(c)(a)(A). As such, MediQuik's monthly
Payments are contemporaneous exchanges for new value given to MediQuik.

     6. Upon payment in full of the MediQuik Obligation, Bayer shall execute a
release of the Judgment and deliver it to MediQuik.

     7. As additional security for MediQuik's obligations to make Payments under
this Agreement and to pay the MediQuik Obligation in full, MediQuik grants to
Bayer a security interest (the "Security Interest") in all of MediQuik's current
and future accounts receivable, until the MediQuik Obligation has been paid in
full. The Security Interest shall be the primary security interest to be granted
by MediQuik in or relating to its accounts receivable, and MediQuik shall
execute and deliver to Bayer all financing statements and other documents that
are necessary or appropriate in order to perfect the Security Interest.

     8. This Agreement, and the payment terms and other terms and conditions
provided for in this Agreement, shall be treated as confidential by MediQuik,
and, except as provided in this Paragraph 8, MediQuik shall not, either directly
or indirectly or by or through anyone else

                                       5
<PAGE>

acting on behalf of MediQuik, disclose or permit to be disclosed to any other
person, firm or entity this Agreement or any other information about this
Agreement, without the prior express written consent of Bayer; provided,
however, that MediQuik may disclose this Agreement and other information about
this Agreement to the extent that it may be legally required to do so by court
order, subpoena or other legal process, after giving Bayer as much prior notice
as is practicable under the circumstances, or as may be required for financial
or tax reporting purposes; and, provided further, that MediQuik may disclose
this Agreement to any potential investors of funds in MediQuik, and to its
accountants, auditors, legal counsel, and directors, and to other persons with
the prior express written consent of Bayer (which consent will not be
unreasonably withheld), provided that such persons have agreed in writing,
before such disclosure is made, to be bound by the confidentiality provisions
contained in this Paragraph 8; and, provided further, that MediQuik may make a
press release and other public announcements about this Agreement by stating
that MediQuik has agreed to satisfy the Judgment on terms mutually agreeable to
Bayer.

     9. This Agreement constitutes the entire agreement of the parties relating
to the subject matter of this Agreement, and this Agreement may not be amended
or modified except by a writing signed by authorized representatives of both
parties.

     10. This Agreement may be executed in two identical counterparts, each of
which shall be deemed to be an original.

     11. This Agreement shall be governed by and construed in accordance with
the laws of the State of New York, without regard to the laws of that state
relating to choice and conflict of laws.

                                       6
<PAGE>

[SIGNATURES ON FOLLOWING PAGE]

                                       7
<PAGE>
\
                                    MEDIQUIK SERVICES, INC.

                                    By   /s/  ROBERT TEAGUE
                                       -----------------------------------------
                                              Robert Teague

                                     Title: Chairman and Chief Executive Officer

                                 ACKNOWLEDGMENT

STATE OF TEXAS           :    SS:
COUNTY OF HARRIS         :

     On this 3rd day of May, 2002, before me, a Notary Public in and for said
county, personally appeared Robert Teague, to me personally known, who, being by
me duly sworn, did state that he is the Chairman and Chief Executive Officer of
MediQuik Services, Inc., the company described in the foregoing Payment
Agreement, that he is fully authorized to execute this Agreement on behalf of
MediQuik Services, Inc., and that this Agreement is the free act and deed of
MediQuik Services, Inc.

                                      /s/  KARLA GUTIERREZ
                                     -------------------------------------------
    [NOTARY SEAL]                    Notary Public

                                     BAYER CORPORATION

                                     By  /s/  JOSEPH MALTA
                                        ----------------------------------------
                                     Title  VP Self Test Business
                                           -------------------------------------

                                 ACKNOWLEDGMENT

STATE OF NEW YORK        :    SS:
COUNTY OF WESTCHESTER    :

     On this 10th day of May, 2002, before me, a Notary Public in and for said
county, personally appeared Joseph Malta, to me personally known, who, being by
me duly sworn, did state that he is the Vice President of Bayer Corporation, the
company described in the foregoing Payment Agreement, that he is fully
authorized to execute this Agreement on behalf of Bayer Corporation, and that
this Agreement is the free act and deed of Bayer Corporation.

                                      /s/  LAURA MEZEY
                                     -------------------------------------------
   [NOTARY SEAL]                     Notary Public

                                       8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00040-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00040-of-00352.parquet"}]]